Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. v. Barr Labs

Executive Summary

Trial suspended on Aug. 19 while FDA and the generic manufacturer negotiate a settlement. In an Aug. 17 opening statement in Newark federal court, attorneys for FDA asked the court to demand a halt in the manufacturing of 15 products, improvements in Barr's production methods and process testing for 45 other products and the recall of 30 lots of products due to "egregious" cGMP violations. Attorneys for Barr, who had expected the government to seek a total shutdown of the generic firm, told the court that Barr is "prepared to make any reasonable accommodation to the government".
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS021385

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel